Clinical Trials

1,314 enrolled 23 charts 1 FDA

Urothelial Cancer

NCT02224781 2026-02-18

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

267 enrolled 8 charts

Melanoma

NCT03143153 2026-02-17

CheckMate 648

970 enrolled 15 charts 1 FDA

Various Advanced Cancer

NCT05002569 2026-01-08

RELATIVITY-098

1,093 enrolled 15 charts

Melanoma

NCT02998528 2026-01-06

CheckMate 816

505 enrolled 17 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03215706 2025-12-17

CheckMate 9LA

719 enrolled 21 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT03907488 2025-12-04

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

994 enrolled 11 charts

Lymphoid

Hodgkin Disease

NCT02743494 2025-11-18

CheckMate 577

794 enrolled 13 charts 1 FDA

Advanced Cancer

NCT02477826 2025-10-30

CheckMate 227

2,747 enrolled 21 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT03906071 2025-10-21

SAPPHIRE

577 enrolled 22 charts

Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT02632409 2025-10-16

CheckMate 274

709 enrolled 13 charts 1 FDA

Various Advanced Cancer

NCT04025879 2025-10-16

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

461 enrolled 18 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04008030 2025-10-03

CheckMate 8HW

839 enrolled 22 charts 1 FDA

Colorectal Neoplasms

NCT04458909 2025-10-03

Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer

15 enrolled 17 charts

Head & Neck

Nasopharyngeal Carcinoma

NCT04149574 2025-09-16

CheckMate 7G8

13 enrolled 11 charts

Urinary Bladder Neoplasms

NCT03937219 2025-09-10

COSMIC-313

855 enrolled 12 charts

Carcinoma, Carcinoma, Renal Cell, Neoplasms

NCT04099251 2025-08-27

CheckMate76K

790 enrolled 18 charts 1 FDA

Melanoma

NCT02872116 2025-08-07

CheckMate649

2,031 enrolled 19 charts 1 FDA

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT02231749 2025-06-26

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

1,390 enrolled 18 charts 1 FDA

Carcinoma, Renal Cell

NCT03522246 2025-06-24

ATHENA

1,097 enrolled 26 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Pathologic Complete Response, Fallopian Tube Neoplasms, Neoplasms

NCT02667587 2025-06-18

CheckMate548

716 enrolled 15 charts

CNS

Brain Neoplasms

NCT04100018 2025-06-12

CheckMate 7DX

1,030 enrolled 25 charts

Prostatic Neoplasms

NCT03141177 2025-06-06

CheckMate 9ER

701 enrolled 17 charts 1 FDA

Carcinoma, Renal Cell

NCT01844505 2025-05-21

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

945 enrolled 19 charts

Melanoma

NCT02388906 2025-04-24

CheckMate 238

906 enrolled 16 charts 1 FDA

Melanoma

NCT03635983 2025-04-01

A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

783 enrolled 24 charts

Melanoma

NCT02576509 2025-02-17

An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma

743 enrolled 16 charts

Carcinoma, Hepatocellular

NCT04109066 2025-01-08

CheckMate 7FL

521 enrolled 17 charts

Breast

Breast Neoplasms, Neoplasms

NCT03138512 2024-12-18

CheckMate 914

1,641 enrolled 21 charts

Carcinoma, Renal Cell, Kidney Neoplasms, Recurrence

NCT04340193 2024-11-26

CheckMate 74W

26 enrolled 15 charts

Liver Neoplasms

NCT02613507 2024-11-19

CheckMate 078

504 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung

NCT03195491 2024-07-18

CheckMate870

400 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02899299 2024-05-21

CheckMate743

605 enrolled 17 charts 2 FDA

Other solid neoplasmThoracic

Mesothelioma

NCT03117049 2024-05-06

Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)

550 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT02864251 2023-09-28

CheckMate722

367 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT02741570 2023-09-21

CheckMate 651

947 enrolled 19 charts

Head & Neck

Head and Neck Neoplasms

NCT02481830 2023-07-27

CheckMate331

569 enrolled 13 charts

Lung Neoplasms

NCT04410445 2023-04-21

PIVOT-12

765 enrolled 13 charts

Melanoma, Skin Neoplasms

NCT03729245 2023-04-11

A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

623 enrolled 14 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02617589 2023-03-28

CheckMate 498

560 enrolled 14 charts

CNS

Brain Neoplasms

NCT02726581 2023-03-27

CheckMate 602

170 enrolled 16 charts

Plasma cell

Multiple Myeloma

NCT02041533 2023-03-02

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

541 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT01673867 2023-02-08

CheckMate057

582 enrolled 18 charts

Non-Squamous Cell Non-small Cell Lung Cancer

NCT02538666 2023-01-05

CheckMate 451

907 enrolled 17 charts

Lung Neoplasms

NCT02066636 2022-10-27

CheckMate153

1,428 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT02105636 2022-10-05

Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)

361 enrolled 14 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT01668784 2022-08-09

Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)

821 enrolled 18 charts

Carcinoma, Renal Cell, Neoplasm Metastasis

NCT01721772 2022-07-12

CheckMate 066

418 enrolled 16 charts

Melanoma

NCT02569242 2022-07-06

Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer

419 enrolled 20 charts 2 FDA